Pharmaceutical research and bio-technology are long term investments that are not traditionally associated with small entrepreneurs
Pharmaceutical research and bio-technology are long term investments that are not traditionally associated with small entrepreneurs. The growth of Yokneam's Startup Village ecosystem attracted high-tech incubators and other sources of funding for Yokneam's budding pharma and bio-tech industry.
BioCEP develops, manufactures and sells cutting-edge technologies for cell isolation, worldwide. Its patented Cell Enrichment Process is incorporated in the CEPir (Cell Enrichment Process for Isolation of Rare Cells) cell isolation device enabling effective immunomagnetic cell isolation for R&D. The CEPir isolates rare cells at high purity and recovery rates offering an alternative to inferior traditional solutions.
The diagnosis of Parkinson's is mainly based on patients' medical history and clinical examination. In some cases Parkinson's disease can be difficult to diagnose with early signs and symptoms being dismissed as the effects of normal aging.
BioShai is developing PDx, a simple blood test for the early diagnosis of Parkinson’s disease. The blood test can be combined with other clinical data to provide a more complete diagnosis to help physicians decide on the best course of treatment.
PDx is based on the measurement of the level of expression of a set of genes. Gene expression is a dynamic process affected by stress, diet, and health leading to dramatic changes in the amount of messenger RNA molecules and protein in the human body over the course of our lives.
Expected to be on the market in 2017.
Innovative treatment for "Dry Eye Syndrome" based on non-invasive magnetic stimulation technology.
It is a known fact that one in 25 patients contracts a healthcare-related bacterial infection during a hospital stay. Using our unique patented process and materials to achieve a long term antibacterial and antibiofilm properties, we have successfully achieved up to 8 log reduction of MARSA, KPC, E. Coli and other resistant bacteria – within minutes. Because the mode of operation is not based on leaching of the coating, we are able to achieve high antibacterial efficacy, over a long period of time.
NanoSono Ltd. (NSC Ltd.) is in the key position to offer a cost-effective solution to a soon-to-be standardized market. In the near future, medical devices, fabrics that are potentially infection causes will require to gain anti-bacterial capabilities to be allowed within patient environments. The most effective way to protect the patients’ and the staffs’ environment is by avoiding the infection in the first place, preferably by eradicating the bacteria from the devices and the equipment that comes in contact with the patients and the hospital stuff. In addition, we make sure the patients’ environment, such as operating rooms, is as sterile as possible, we are also focused on lowering the risk of infection by making “carrier” materials within the patients’ direct environment such as robes, linens etc. anti-bacterial.
NanoSpun develops and produces smart fibrous mats and surfaces which significantly improve biological processes. NanoSpun utilizes its proprietary nanotechnology, impressively controlled over the fiber properties and unique embodiment capabilities, to encapsulate designated active microorganisms within its fibrous permeable structures.
NanoSpun solution offers fundamental advantages over other competing technologies and its resulting products demonstrate efficient, cost-effective and easy to operate solutions which represent leapfrog advancement for humankind and sustainable environment.
Glaucoma is an optic neuropathy disease, stems from prolonged increase in intraocular pressure (IOP), resulting in a progressive retinal ganglion cell, axonal loss, visual field defects and eventually blindness, because of the permanent cellular and neuronal damage in the eye.
NeurOptic Company is developing a new therapeutic strategy for glaucoma, based on approved drug, indicated as therapy of neurodegenerative disease, which is a different class from the drug classes currently used for the treatment of glaucoma. Pre-clinical studies showed that the novel topical treatment exerted a significant effect on high levels of IOP and may prevent neuronal damage in the eye.
NextFerm is a science oriented industrial company, representing a new era in fermentation and fermentation-derived nutrients for supplements, food, infant nutrition and animal feed.
Bringing the World Better Nutrition
The world is striving for better nutrition. Nutrition which is less artificial and more natural, sustainable and cost effective - with a much higher nutritional value. At Nextferm, we aim to use our capabilities to lead this new and exciting world of better nutrition.
Foodtech startup for production of natural food colorants.
Phytolon’s activity consists at developing a novel technology for the production of pure, stable, cheap and healthy natural food colorants by fermentation. With this technology, we offer an appropriate substitute for the harmful synthetic colorants and for the currently used insufficient natural colorants.
Phytolon operates as a portfolio company of the Trendlines incubator, and is funded by the Israeli Innovation Authority since August 2018.
RayFund is a mass participation fundraising platform for small entrepreneurs to enable them to raise capital for the long term investments required for pharmaceutical research and bio-technology. Our goal is to take market control out of the hands of giant companies who acquire patents and prevent others from competing with them in the market, thereby raising prices in medication instead of benefiting patients.
Eroll Grow Tech (Seedo) developed the world's first fully-automated device managed and controlled by an artificial intelligent algorithm and monitored by smart phone App. In August 2018 Eroll Grow Tech (Seedo) and Cannabics Pharmaceuticals (https://cannabics.com/) announced an agreement to develop a fully automated controlled device for growing medical cannabis at home. The product will be managed and controlled by an AI algorithm and monitored by a smartphone app.
For the past decade, Bara Herbs has been the leader of the future herbal medicine, through means of research and development, production, marketing and the setting up of a knowhow center for professionals. Bara's herbal products are well known for their therapeutic creativity and the highest quality of raw materials. The company specializes in the extraction and processing of more than 700 quality medicinal herbs from Israel and around the world.
The development of Bara's herbal products is based on extensive clinical experience, scientific research collaborations and most innovative production technologies – all of which guarantee the purest, whole extraction of each herb, upon its full spectrum of bioavailable constituents. Bara's herbal-based products are easy to integrate into the daily routine as they are available in various forms including tinctures, capsules, tablets, teas, syrups, ointments and oils.